Journal article

Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes

Jinny Min, Stanley Cohan, Enrique Alvarez, Jacob Sloane, J Theodore Phillips, Anneke van der Walt, Irene Koulinska, Fang Fang, Catherine Miller, Andrew Chan

Neurology and Therapy | SPRINGER LONDON LTD | Published : 2019


INTRODUCTION: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategies on the occurrence of GI events and discontinuation patterns. METHODS: Data on GI events and DMF persistence were retrospectively abstracted from medical records of patients treated with DMF in routine medical practice in the EFFECT study (NCT02776072). GI management strategies were assessed via a study site questionnaire. Discontinuation rates were analyzed according to counseling patterns. RES..

View full abstract


Funding Acknowledgements

This study was sponsored by Biogen (Cambridge, MA, USA). All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Biogen funded the article processing charges.